<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496794</url>
  </required_header>
  <id_info>
    <org_study_id>100487</org_study_id>
    <nct_id>NCT01496794</nct_id>
  </id_info>
  <brief_title>Endophthalmitis Cultures</brief_title>
  <acronym>PROSPER</acronym>
  <official_title>Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this surveillance study will be to obtain written permission from patients with
      bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial
      isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with
      vancomycin, ceftazidime, and moxifloxacin.

      Research hypothesis:

        1. Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with
           combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to &quot;standard
           therapy&quot; with vancomycin and ceftazidime.

        2. Longitudinal analysis of resistance patterns of cultured isolates will show increasing
           rates of multi-antibiotic resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>Endophthalmitis</condition>
  <arm_group>
    <arm_group_label>Endophthalmitis cultures</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Vanderbilt Eye Institute
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all adult patients age 18 or greater presenting with bacterial endophthalmitis to the
             Vanderbilt Eye Institute and who grow positive cultures

        Exclusion Criteria:

          -  Patients &lt; 18 years of age or those patients without positive cultures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Stephen J. Kim, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

